Abbott Laboratories (NYSE:ABT) Price Target Cut to $140.00 by Analysts at BTIG Research

Abbott Laboratories (NYSE:ABT) had its target price decreased by investment analysts at BTIG Research from $145.00 to $140.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the healthcare product maker’s stock. BTIG Research’s target price suggests a potential upside of 29.03% from the stock’s current price.

Other research analysts also recently issued reports about the company. Raymond James Financial boosted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a research note on Thursday, October 16th. Evercore ISI upped their price target on shares of Abbott Laboratories from $142.00 to $144.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Finally, Mizuho upped their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $146.56.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $108.50 on Friday. The stock has a market capitalization of $188.67 billion, a P/E ratio of 13.60, a P/E/G ratio of 2.00 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company’s 50-day moving average is $125.23 and its 200 day moving average is $128.54. Abbott Laboratories has a 1 year low of $105.78 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Institutional Trading of Abbott Laboratories

Large investors have recently added to or reduced their stakes in the stock. IMG Wealth Management Inc. raised its holdings in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the period. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the 3rd quarter worth $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories in the third quarter worth $31,000. Finally, Anfield Capital Management LLC grew its position in Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Med‑tech strength and margin expansion: Abbott said its Devices/MedTech businesses performed well in Q4 and reported adjusted EPS growth of ~12%, which supports longer‑term earnings power. Abbott Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Analyst support and income profile: Many sell‑side analysts maintain buy/outperform ratings and above‑current price targets, and the company’s Dividend‑King status and buyback capacity are cited as reasons some investors view the recent pullback as a buying opportunity. Is Abbott’s January Pullback a Good Time to Buy?
• Neutral Sentiment: Q4 EPS matched consensus: Abbott reported adjusted EPS of $1.50, in line with estimates — a neutral datapoint that limits the positive surprise potential. Abbott (ABT) Matches Q4 Earnings Estimates
• Negative Sentiment: Revenue miss and segment weakness: Total Q4 revenue of $11.46B fell short of Street estimates (~$11.8B). Weakness in Diagnostics (volatile post‑COVID testing) and a ~9% decline in Nutrition weighed on top‑line growth, prompting investor concern. Abbott misses quarterly revenue estimates on weakness in diagnostics segment
• Negative Sentiment: Guidance disappointed modestly: Q1 EPS guidance (1.12–1.18) is below consensus (~1.20) and FY adjusted EPS range (5.55–5.80) leaves limited upside vs. Street forecasts, which amplified the sell‑off after results. Abbott Reports Fourth-Quarter and Full-Year 2025 Results
• Negative Sentiment: Regulatory/legal risk in India: Documents show scrutiny of an Abbott Healthcare (India) supply chain tied to alleged misuse of a codeine‑based cough syrup — a developing regulatory issue that adds uncertainty and headline risk. Abbott faces India scrutiny in cough syrup abuse investigation, documents show
• Negative Sentiment: Options flow and investor positioning: There was a large uptick in put buying (≈80.6k puts), indicating elevated bearish bets or hedging demand that can accelerate downside during news flows. (trade flow reported by market sources)

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.